Payload Information

General Information of This Payload
Payload ID
PAY0XXDJK
Name
P1003
Synonyms
P1003
   Click to Show/Hide
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Structure
Formula
C29H28FN3O6
Isosmiles
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2C(NC(=O)C1CC(O)C1)CC3
InChI
InChI=1S/C29H28FN3O6/c1-3-29(38)18-8-22-25-16(10-33(22)27(36)17(18)11-39-28(29)37)24-20(32-26(35)13-6-14(34)7-13)5-4-15-12(2)19(30)9-21(31-25)23(15)24/h8-9,13-14,20,34,38H,3-7,10-11H2,1-2H3,(H,32,35)
InChIKey
HXGGSZGIFKOKFK-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
533.556
Polar area
130.75
Complexity
39
xlogp Value
2.40152
Heavy Count
39
Rot Bonds
3
Hbond acc
8
Hbond Donor
3
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
DB-1303 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
44.20
50.00% (HER2-positive BC)
38.50% (HER2-Low BC)
66.70% (CRC)
50.00% (EsC)
50.00% (OC)
33.30% (EC)
Patients Enrolled
Pretreated advanced or metastatic solid tumors; Histologically confirmed HER2-positive or HER2- expressing cancers.
Administration Dosage
2.20 - 12.00 mg/kg Q3W.
Related Clinical Trial
NCT Number NCT05150691  Phase Status Phase 1/2
Clinical Description
A phase 1/2a, multicenter, open-label, non-randomized first in human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors.
DB-1305 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05438329  Phase Status Phase 1/2
Clinical Description
A phase 1/2a, multicenter, open-label, non-randomized first in human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1305 in subjects with advanced/metastatic solid tumors.
References
Ref 1 A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors. Cancer Res (2023) 83 (8_Supplement): CT247.
Ref 2 A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors, NCT05438329

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.